Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.

Kim YI, Kim SK, Paeng JC, Lee HY.

Eur J Radiol. 2014 Jan;83(1):231-5. doi: 10.1016/j.ejrad.2013.09.031. Epub 2013 Nov 14.

PMID:
24290142
[PubMed - indexed for MEDLINE]
2.

Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.

Guan ZW, Xu BX, Wang RM, Sun L, Tian JH.

Hell J Nucl Med. 2013 May-Aug;16(2):97-102. doi: 10.1967/s002449910084. Epub 2013 May 20. Review.

PMID:
23687644
[PubMed - indexed for MEDLINE]
Free Article
3.

FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Chung HW, Lee KY, Kim HJ, Kim WS, So Y.

J Cancer Res Clin Oncol. 2014 Jan;140(1):89-98. doi: 10.1007/s00432-013-1545-7. Epub 2013 Nov 6.

PMID:
24194352
[PubMed - indexed for MEDLINE]
4.

18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.

Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S.

Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9.

PMID:
18043094
[PubMed - indexed for MEDLINE]
5.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
[PubMed - indexed for MEDLINE]
6.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
[PubMed - indexed for MEDLINE]
7.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
[PubMed - indexed for MEDLINE]
8.

Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.

Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.

J Nucl Med. 2013 Jul;54(7):1032-8. doi: 10.2967/jnumed.112.116053. Epub 2013 May 13.

PMID:
23670902
[PubMed - indexed for MEDLINE]
Free Article
9.

Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.

Liao S, Penney BC, Zhang H, Suzuki K, Pu Y.

Acad Radiol. 2012 Jan;19(1):69-77. doi: 10.1016/j.acra.2011.08.020.

PMID:
22142679
[PubMed - indexed for MEDLINE]
10.

Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.

Sato M, Okumura T, Kaito K, Kiyoshima M, Asato Y, Uchiumi K, Iijima H, Hashimoto I, Kaburagi T, Amemiya R.

Ann Nucl Med. 2009 Jan;23(1):49-57. doi: 10.1007/s12149-008-0205-5. Epub 2009 Feb 11.

PMID:
19205838
[PubMed - indexed for MEDLINE]
11.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640
[PubMed - indexed for MEDLINE]
12.

Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma.

Lee SJ, Choi JY, Lee HJ, Baek CH, Son YI, Hyun SH, Moon SH, Kim BT.

Korean J Radiol. 2012 Nov;13(6):752-9. doi: 10.3348/kjr.2012.13.6.752. Epub 2012 Oct 12.

PMID:
23118574
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.

Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, Su Z, Pai J, Oteiza KE, Griffith ME, Wahl RL, Tryggestad E, Pawlik T, Laheru DA, Wolfgang CL, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):539-46. doi: 10.1016/j.ijrobp.2014.02.031. Epub 2014 Apr 18.

PMID:
24751410
[PubMed - indexed for MEDLINE]
14.

Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.

Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase K, Fukuda H, Takahashi S.

Ann Nucl Med. 2011 Aug;25(7):501-10. doi: 10.1007/s12149-011-0494-y. Epub 2011 May 3.

PMID:
21537945
[PubMed - indexed for MEDLINE]
15.

Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.

Moon SH, Kim HS, Hyun SH, Choi YS, Zo JI, Shim YM, Lee KH, Kim BT, Choi JY.

J Nucl Med. 2014 May;55(5):743-8. doi: 10.2967/jnumed.113.130716. Epub 2014 Apr 3.

PMID:
24700884
[PubMed - indexed for MEDLINE]
16.

Evaluation of pancreatic carcinoma with FDG PET.

Jadvar H, Fischman AJ.

Abdom Imaging. 2001 May-Jun;26(3):254-9.

PMID:
11429948
[PubMed - indexed for MEDLINE]
17.

F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.

Sperti C, Pasquali C, Decet G, Chierichetti F, Liessi G, Pedrazzoli S.

J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9.

PMID:
15623441
[PubMed - indexed for MEDLINE]
18.

Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.

Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.

Invest Radiol. 2014 Jan;49(1):7-14. doi: 10.1097/RLI.0b013e3182a4eb4a.

PMID:
24002080
[PubMed - indexed for MEDLINE]
19.

Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?

Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.

Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):331-8.

PMID:
18330088
[PubMed - indexed for MEDLINE]
20.

Diagnostic usefulness of FDG PET for pancreatic mass lesions.

Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H, Yamada R.

Ann Nucl Med. 2001 Jun;15(3):217-24.

PMID:
11545191
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk